文献速递免疫规划传染病防控与疫情报告

COVID-19疫苗与感染诱导免疫的持久性:系统综述与Meta回归分析

Durability of COVID-19 vaccine and infection induced immunity: A systematic review and meta-regression analysis.
PubMed 文献 · Vaccine · 2025-03-05

该研究系统检索2020年1月1日至2023年1月1日PubMed、medRxiv和bioRxiv中评估mRNA疫苗接种和既往SARS-CoV-2感染相对未感染者的疫苗有效性的研究,纳入123项研究进行Meta回归。结果显示,针对感染和疾病的疫苗有效性随时间及Omicron出现而下降,但针对重症结局的保护更持久;加强针在接种后2周和26周对重症Omicron感染的保护分别为90.5%和77.6%;混合免疫比单独接种或既往感染更持久,但接种后26周对Omicron再感染的保护仅50.1%。

要点

  • 疫苗对感染和疾病的保护随时间及Omicron出现而下降,对重症结局的保护更持久。
  • 加强针在接种后2周和26周对重症Omicron感染的保护分别为90.5%和77.6%。
  • 混合免疫者接种加强针后保护为80.6%,16周后降至36.9%。

核心结论

  • 结果提示,及时部署现有加强针可大幅减轻季节性COVID暴发,即使是在既往感染和接种疫苗的人群中。

研究设计与样本

  • 系统综述与Meta回归分析,检索PubMed、medRxiv和bioRxiv于2020年1月1日至2023年1月1日发表的研究,最终纳入123项研究。
  • 纳入标准为测量mRNA疫苗接种和既往SARS-CoV-2感染相对未感染者的疫苗有效性(感染、有症状疾病和重症疾病减少),排除未区分mRNA与非mRNA疫苗或参与者少于1000人的研究。
  • 采用多水平模型量化接种或感染后初始有效性及4至6个月内的变化,模型协变量包括COVID变异株、疫苗剂次、既往感染次数和变异株,估计值按研究人群年龄调整。

主要发现

  • 疫苗对感染和疾病的有效性随时间及Omicron出现而下降,无论是否接种加强针,但针对重症结局的保护更持久。
  • 加强针在接种后2周和26周对重症Omicron感染的保护分别为90.5%(95%CI 87.1-93.8)和77.6%(95%CI 70.5-84.7)。
  • 混合免疫提供的保护比单独接种或既往感染更持久,但接种后26周对Omicron再感染的保护仅为50.1%(95%CI 32.5-67.8)。
  • 混合免疫个体在接种加强针后保护为80.6%(95%CI 70.0-91.2),16周后降至36.9%(95%CI 19.3-54.6)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the success of mRNA vaccines, COVID-19 remains a significant public health threat. Waning of immune memory and the emergence of new variants can degrade population-level protection and contribute to ongoing morbidity. METHODS: In this systematic review and meta-regression, we searched for studies in PubMed, medRxiv and bioRxiv published January 1, 2020 - January 1, 2023 measuring vaccine effectiveness as the reduction in infection, symptomatic disease, and severe disease (resulting in hospitalization and/or death) conferred by mRNA-based vaccination and prior SARS-CoV-2 infections relative to naïve individuals. We excluded studies that did not distinguish between mRNA and non-mRNA vaccines or had less than 1000 participants. Using a multi-level model, we quantified the initial effectiveness and change over four to six months following vaccination or infection. Model covariates were COVID variant, number of vaccine doses, and the number and variant of prior infection. Our estimates were adjusted for the age of the study population. FINDINGS: Of 828 screened, we included 123 studies in our analysis. Vaccine effectiveness against infection and disease declined both over time and with the emergence of Omicron, regardless of booster doses, though protection against severe outcomes was more durable. Booster doses reduced severe Omicron infections by 90.5 % (95 % confidence interval 87.1-93.8) and 77.6 % (70.5-84.7) at two and 26 weeks post-vaccination, respectively. Protection conferred by hybrid immunity was more durable than that from either vaccination or prior infection alone, but protection against Omicron reinfection was only 50.1 % (32.5-67.8) at 26 weeks following vaccination. Individuals with hybrid immunity had 80.6 % protection (70.0-91.2) following booster doses declining to 36.9 % (19.3-54.6) after 16 weeks. INTERPRETATION: Our results suggest that timely deployment of pre-existing boosters can greatly mitigate seasonal COVID outbreaks even in populations with prior infection and vaccination. FUNDING: Centers for Disease Control and Prevention (NU38OT000297-03).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Moore M, Anderson L, Schiffer JT, et al. Durability of COVID-19 vaccine and infection induced immunity: A systematic review and meta-regression analysis. Vaccine. 2025. PMID: 40048931. doi:10.1016/j.vaccine.2025.126966

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。